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The management of rheumatoid arthritis has
undergone major advances in recent years, both in
terms of the drugs armamentarium and therapeutic
strategy. Treating disease to target, aiming at
remission, through a tight control protocol is regarded
as the standard of care. Reaching clinical and
radiographic disease remission has therefore become
an achievable goal. Increasing evidence has
demonstrated that early diagnosis, prompt treatment
initiation and early achievement of remission are the
major predictors of long-term clinical, functional and
radiographic outcomes. Concentrating efforts in
controlling disease activity in a very early window of
opportunity offers unique sustained benefits. In this
short review, we analysed the available evidence
supporting the value of treating rheumatoid arthritis
early and the impact on disease outcomes, with
particular focus on radiographic progression.
INTRODUCTION
The treatment strategy of rheumatoid arth-
ritis (RA) has undergone major changes in
the past decades. The introduction of
disease-modifying antirheumatic drugs
(DMARDs) and targeted biologic-DMARDs
(bDMARDs) has broadened the therapeutic
possibilities, making clinical and radio-
graphic remission an achievable goal. The
increasing awareness of the prognostic
impact of treating disease to target (T2T),
adjusting therapy according to disease activ-
ity, has further optimised the outcomes.1 The
evidence from trials using early intensive
DMARD strategies introduced the concept of
‘window of opportunity’ and gave rise to
early RA (ERA) clinics, supported by the
long-term remission, as well as functional,
radiographic and prognostic outcomes of
starting treatment early.2–4
METHODS
This was a narrative review aiming at discuss-
ing the importance of early diagnosis and
prompt treatment in RA and analysing the
long-term beneﬁts on several outcomes.
Combined automated and manual literature
searches were performed on PubMed using
the search terms ‘early rheumatoid arthritis’
AND ‘rheumatoid arthritis’ AND [‘diagnosis’
OR ‘treatment’ OR ‘tight control’ OR ‘treat
to target’ OR ‘radiographic progression’ OR
‘outcomes’]. From the resulting papers,
manual searches were performed to ﬁnd
relevant information on the research topic.
BENEFITS OF EARLY RA DIAGNOSIS AND
TREATMENT
National and International recommenda-
tions address the importance of starting
DMARD therapy as soon as the diagnosis of
RA is made.5 Data from multiple observa-
tional cohorts and clinical trials indicate that
treatment initiation in the ﬁrst 12 weeks
since disease onset is particularly effective in
controlling disease activity and results in
better mid-term and long-term outcomes.
The FinRaCo trial demonstrated that a delay
in therapy (>4 months) was the only signiﬁ-
cant predictor of remission using a
single-DMARD strategy.6 According to the
‘window of opportunity’ hypothesis, the time
to intervention within a limited time frame is
Key messages
▸ Early rheumatoid arthritis (RA) diagnosis with
promt initiation of treatment and precocious
achievement of remission are the major predic-
tors of long-term clinical, functional and radio-
graphic outcomes.
▸ The concept of ‘window of opportunity’ set
within the first 12 weeks since disease onset
has been demonstrated to offer unique sus-
tained and long-term benefits. Such early time
frame of intervention still needs to be optimised
in everyday clinical practice.
▸ This short review analyses the available evidence
on the topic of early diagnosis and treatment of
RA, with particular focus on the impact on
radiographic progression.
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associated with a particularly effective response to
therapy, resulting in long-term sustained outcomes. A
recent study on two large cohorts of patients from early
clinics (Leiden Early Arthritis Clinic and ESPOIR) set
this critical time point for DMARD introduction to
11.4 weeks from symptoms onset for anticitrullinated
protein antibodies (ACPA)-positive RA and 15 weeks for
ACPA-negative subjects, supporting the concept of two
different pathological subsets of disease.6 The primary
outcome was conventional synthetic DMARD
(csDMARD)-free sustained remission up to 5 years of
follow-up, still possible for a minority of patients (11.5%
and 5.4% in the 2 cohorts), but that is strictly related to
the inﬂammatory load before treatment is started.7 Very
ERA (VERA), deﬁned as symptom duration ≤12 weeks,
has also been demonstrated as a predictor of remission
in a large multicentre real-life prospective study includ-
ing 1795 patients. The follow-up analysis up to
12 months was restricted to 481 patients presenting with
at least Disease Activity Score (DAS28) moderate disease
activity at baseline. DAS28 remission was achieved in
34.3% (ranging 19.5–49%) of patients with RA and was
signiﬁcantly associated with a diagnosis of VERA and an
intervention with csDMARDs in the ﬁrst 12 weeks of
disease duration as shown in table 1.8
The superiority of functional and structural outcomes
is particularly evident not only compared with established
RA, but also compared with late ERA characterised by a
median symptom duration of 12 months, even if still clas-
siﬁable within the relatively ﬂexible deﬁnition of early
arthritis.9 A delayed rheumatological referral
(≥12 weeks) has been associated with a long-term impact,
leading to an HR of 1.87 for not achieving DMARD-free
remission and a 1.3 times higher rate of joint destruction
over 6 years. Unfortunately, despite the robust-evidence
supporting the relevance of a window of opportunity,
only 31% of patients with RA were assessed <12 weeks in a
real-life setting of 1674 patients with early arthritis.10
A meta-analysis of 18 available randomised controlled
trials (RCT) also reported that prolonged symptom
duration before DMARD treatment initiation is inde-
pendently associated with radiographic progression and a
lower chance on DMARD-free sustained remission.11
Data from the ESPOIR cohort including 661 patients
with early arthritis have stressed the favourable effect of
very early DMARD initiation, within 3 months from diag-
nosis, in reducing 12-month radiographic progression.12
Some authors argue that, when dealing with such pre-
cocious disease, there might be some degree of over-
diagnosis for patients whose disease would eventually
resolve without DMARDs; however, this risk has been
demonstrated to be very low: 8% with 2010 European
League Against Rheumatism–American College of
Rheumatology (EULAR/ACR) criteria for RA compared
to 2% with 1987 criteria.13 In 2013, erosive disease,
highly speciﬁc of RA, has been ﬁnally deﬁned as a radio-
graphic erosion involving at least three separate joints in
the hands, wrists and feet, allowing a better diagnostic
conﬁdence.13 Moreover, among patients with ERA/
undifferentiated arthritis, a score of the 2010 ACR/
EULAR criteria sufﬁcient to classify RA has been
demonstrated to select patients with worse clinical
outcome and more radiographic progression, therefore
needing aggressive treatment.14 The risk of misclassify-
ing other conditions such as palindromic rheumatism is
also low as far as the diagnosis of RA is committed to an
expert rheumatologist. Palindromic rheumatism is a
recognised clinical entity that is typically monoarticular,
with a very short duration of attacks (in the majority of
cases less than 48 h and always shorter than a week).
With such a presentation, it is quite unlikely that a
patient would either fulﬁl RA classiﬁcation criteria or be
diagnosed with RA. The frequency of palindromic
rheumatism is far lower than that of RA and has been
estimated to be one-twentieth that of RA, making mis-
classiﬁcation less probable. Moreover, the condition may
preclude the onset of other rheumatic conditions, espe-
cially RA, in a signiﬁcant proportion of patients, particu-
larly when ACPA or rheumatoid factor is detected.15
BENEFITS OF ACHIEVING REMISSION WITH A T2T AND
TIGHT CONTROL STRATEGY
Further evidence that the strategy is sometimes more
important than the agent used to treat RA comes from a
number of RCT supporting the T2T and tight control
Table 1 Factors predicting 12-month DAS28 remission in
a cohort of patients with early arthritis
Population of general characteristics
Total number of pts with ERA 481
Total number of pts with VERA 148 (30.8)
Remission after 12 months; n (%) 165 (34.3)
Erosive disease; n (%) 168 (34.9)
csDMARDs only; n (%) 329 (68.4)
bDMARDs; n (%) 152 (31.6)
VERA pts; n (%) 105 (21.82)
csDMARDs only among VERA pts;
n (%)
95 (90.5)
bDMARDs among VERA pts; n (%) 10 (9.5)
Multivariate analysis model predicting remission
Variable OR (95% CI)
DAS28 t0 <5.1 1.54 (0.94 to 2.51)
HAQ t0 <1.5 1.29 (0.75 to 2.23)
VERA 2.03 (1.25 to 3.30)
Anti-CCP positive 1.39 (0.94 to 2.07)
Erosions t0 0.47 (0.29 to 1.08)
DMARD in the first 3 months 1.65 (1.06 to 2.55)
Significant results are shown in bold.
Analysis restricted to patients with ERA with a baseline moderate–
high disease activity (n=481). (Adapted from Gremese et al).8
bDMARDs, biologic disease-modifying anti-rheumatic drugs, CCP,
cyclic citrullinated protein; csDMARDs, conventional
synthetic-DMARDs, DAS28, disease activity score in 28 joints;
ERA, early rheumatoid arthritis; HAQ, health assessment
questionnaire; pts, patients; t0, baseline; VERA, very ERA.
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approach.12 13 The TICORA study analysed the differ-
ences between a sustained, tight control, DAS-driven
approach to RA compared with clinical routine out-
patient care, reporting an EULAR good response in
82% of patients in the intensive care group compared
with 44% in the control group. An intensive manage-
ment of RA also resulted in reduced radiographic pro-
gression (change in the total sharp radiographic score
of 4.5 vs 8.5), physical function and quality of life, with
no additional costs. The CAMERA trial also demon-
strated the superiority of an intensive methotrexate
(MTX) regimen with the T2T and tight control
approach in ERA (<1 year disease duration) in reaching
remission compared to usual care (DAS28-remission rate
50% vs 37%).16 The recently licensed EULAR guidelines
state that treatment should be aimed at reaching a
target of remission or low disease activity in every
patient, following strict (every 1–3 months) clinical mon-
itoring and adjusting therapy according to disease activ-
ity. Prognostic factors are important in adapting step-up
treatment to bDMARDs. An overview of a large incep-
tion cohort from 1989 to 2009 investigating the improve-
ment in outcomes related to the new treatment strategy
reported signiﬁcantly decreased disease activity and joint
damage progression, increased functional ability
(Health Assessment Questionnaire -HAQ) and fewer
orthopaedic interventions.17 Real-life data on early arth-
ritis cohorts have demonstrated remission rates as high
as those achieved in RCT following a tight control proto-
col aiming at remission (DAS28-remission 55% vs 30%
in usual care).18 Achieving clinical remission, regardless
of the criterion used to deﬁne it (ACR/EULAR,
Simpliﬁed Disease Activity Index (SDAI), DAS28), is
indeed associated with a better control of disease, both
in terms of functional disability and objectivable synovitis
with power doppler positivity at sonographic evaluation,
known to correlate with radiographic progression.19
A recent Italian rheumatologists’ survey on the accept-
ance of the T2T recommendations reported a high level
of knowledge and agreement with the guidelines state-
ments, conﬁrming that this is becoming a consolidated
standard of care also in everyday clinical practice.20
BENEFITS OF REACHING THE TARGET OF REMISSION EARLY
As mentioned above, early diagnosis with prompt treat-
ment initiation and a tight control follow-up aiming at
remission should be regarded as the standard of care in
the management of RA. Evidence has also demonstrated
that the timing to achieve remission has a fundamental
prognostic role: earlier time to remission predicts sus-
tained clinical remission in ERA. Sustained remission
represents the desired goal, being associated with long-
term improvement of quality of life, physical function
and reduced radiographic progression.21 Long-term per-
sistence of remission is possible in about half of the
patients meeting remission criteria.21 22 Predictive factors
of reduced rates of sustained remission have been identi-
ﬁed in female sex, greater pain, lack of initial DMARD
therapy and older age.21 22 A shorter time to remission
has been a consistent and strong determinant of sus-
tained remission. Schipper et al demonstrated that earlier
time to remission is the strongest predictor of sustainabil-
ity over a 20-year period, regardless of the type of treat-
ment.22 Disease duration is among the most relevant
factors affecting the likelihood of patients’ response to
treatment,19 20 even when bDMARDs are prescribed.23 24
In ERA (diagnosis of RA with symptoms duration <12
months), low-dose prednisone comedication has been
reported to be associated with earlier disease activity
Figure 1 The effect of early response to treatment on 5-year follow-up of radiographic progression rate. Adapted from Bakker
et al28 (EULAR, European League Against Rheumatism; SHS, Sharp van der Heijde score, median values).
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control, higher rates of clinical remission and a more
stable and sustained remission over time.25 Early remis-
sion signiﬁcantly affects long-term outcomes. The 11-year
results of the FIN-RACo trial showed that treating ERA
with traditional DMARDs, targeting to remission and
with tight clinical control results in low radiological pro-
gression in most patients; interestingly, long-term radio-
graphic progression (Larsen score) up to 11 years of
follow-up was signiﬁcantly lower in patients reaching
remission in the ﬁrst year of treatment.26 Data from the
CAMERA study also conﬁrmed how early clinical
response to MTX treatment can affect 5-year clinical and
radiographic (Sharp-van der Heijde score) outcomes27
(ﬁgure 1). The same clinical, functional and structural
outcomes, with a strict connection between time to treat-
ment response and long-term beneﬁts, have been
reported for several bDMARDs.28–30 Real-life data from
ERA patients recruited in the ESPOIR cohort (<6
months of disease duration with a certain of probable RA
clinical diagnosis) and treated according to the standard
of care with csDMARDs and/or bDMARDs, conﬁrm the
long-term detrimental effects of failing to reach good
disease control during the ﬁrst 12 months. Indeed, per-
sistent moderate disease activity during the ﬁrst year of
disease is associated with greater radiographic progres-
sion at 3 years, increased HAQ up to 5 years, ﬁve-time
increase in missed workdays and approximately a 10-fold
smaller chance of achieving clinical remission in the long
term24
Striving to early remission in RA also empowers
further, more comprehensive implications. Rapid
induction of remission is essential to maintain workabil-
ity in patients with ERA; remission in the ﬁrst year is an
independent predictor of preserved working capacity
and social productivity in the future.27 Studies investi-
gating functional ability and health-related quality of
life have also found the advantage of early remission in
guaranteeing better or even normalised outcomes.31
Early treatment resulting in tight inﬂammation control
and remission, also in the ERA setting, is strictly asso-
ciated with improvement in cardiovascular risk and
reduction of cardiovascular morbidity.32–34 Results from
the Norfolk Arthritis Register demonstrated that early
and sustained remission is associated with improved
survival. Achievement of remission within the ﬁrst
3 years of disease determined a fall of about 30% in the
risk of all-cause mortality. Lowest risk of death was asso-
ciated with the earliest and most persistent status of
remission.35–37
CONCLUSIONS
It is highly consistent throughout the available literature
that early diagnosis, prompt treatment initiation and
early achievement of the desirable target of remission in
RA offer a unique opportunity to change the course of
disease, ameliorating all functional, radiographic, socio-
economic and prognostic outcomes.
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